Home > Insider Trading > Filing (0000899243-20-019424)

Filing Details

Accession Number:: 0000899243-20-019424
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-16 20:00:30
Reporting Period:: 2020-07-14

Accepted Time:: 2020-07-16 20:00:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1340652	Chemocentryx Inc.	CCXI	Pharmaceutical Preparations (2834)	943254365

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1416422	Ltd. Pharma Vifor	Rechenstrasse 37 Ch-9014 St. Gallen V8	No	No	Yes	No
1675217	Ltd (International) Vifor	Rechenstrasse 37 Ch-9014 St. Gallen V8	No	No	Yes	No
1757924	Ltd. Pharma Renal Care Medical Fresenius Vifor	Rechenstrasse 37 Ch-9014 St. Gallen V8	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-14	13,027	$56.91	10,064,096	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-14	68,732	$58.16	9,995,364	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-14	18,241	$58.62	9,977,123	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-15	22,313	$58.65	9,954,810	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-15	63,985	$59.43	9,890,825	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-16	27,340	$56.03	9,863,485	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-16	20,801	$56.77	9,842,684	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-16	18,888	$57.99	9,823,796	No	4	S	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Disposition	2020-07-16	6,471	$58.55	9,817,325	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities").
Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 6,483,992 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP.
Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Vifor on June 26, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.51 to $57.50, inclusive. Vifor undertakes to provide ChemoCentryx, Inc., any security holder of ChemoCentryx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.57 to $58.56, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.02, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.97 to $58.96, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.97 to $59.85, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.43 to $56.42, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.43 to $57.42, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.43 to $58.42, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.43 to $58.93, inclusive.